Cardiotoxicity associated with 5-fluorouracil (FU) is an uncommon, but potentially lethal, condition. The case of an 83-year-old man with colon cancer who developed chest pain during 5-FU infusion is presented. The electrocardiogram (ECG) showed pronounced ST elevation in the lateral leads, and the chest pain was resolved after infusion of nitroglycerin. A coronary angiogram (CAG) revealed that the patient had significant atherosclerosis in the proximal left circumflex artery. Coronary artery spasm with fixed stenosis was considered, and a drug-eluting stent was implanted. After 8 hours, the patient complained of recurring chest pain, paralleled by ST elevation on the ECG. The chest pain subsided after administration of intravenous nitroglycerin followed by sublingual nifedipine. Repeated CAG showed patency of the previous stent. This case supports the vasospastic hypothesis of 5-FU cardiac toxicity, indicating that a calcium channel blocker may be effective in the prevention or treatment of 5-FU cardiotoxicity.
INTRODUCTION
The antimetabolite 5-fluorouracil (FU) is widely used in the treatment of solid tumors, including gastrointestinal, breast, head, and neck cancers. Cardiotoxicity, a rare adverse effect of 5-FU, has a reported incidence of 1.2% to 18% [1, 2] . The pathogenesis of 5-FU cardiotoxicity is unclear. The prevalent hypothesis suggests that 5-FU induces coronary vasospasm [1] . We report here a case of 5-FU cardiotoxicity. The patient presented with typical angina and electrocardiographic changes suggestive of an ischemic coronary event during the continuous infusion of 5-FU. The ischemia recurred when the infusion was stopped, and was relieved by administration of nitroglycerin followed by a sublingual calcium channel blocker.
CASE REPORT
An 83-year-old man who had been diagnosed with stage 
A B
he reported a recurrence of the anterior chest pain. The ECG also showed ST segment elevation and reciprocal ST changes similar to those seen in the previous ischemic events (Fig. 1B) . The chest pain and ECG changes persisted despite a 100 µg/min nitroglycerin infusion. To rule out acute stent thrombosis, the patient was taken to the cardiac catheterization laboratory. The chest pain and ECG changes were relieved after sublingual administration of 10 mg nifedipine. Repeated coronary angiography showed a widely patent stent (Fig. 4) . The postprocedural troponin-I and CK-MB levels were 0.010 and 4.62 ng/ mL, respectively. Echocardiography performed the next day also showed the absence of the regional wall motion abnormality and normal left ventricular systolic function. The patient refused chemotherapy and was discharged in a stable condition. He remained free of the symptoms of recurrent angina pectoris.
DISCUSSION
We present here a case of severe cardiotoxicity mimicking acute anterolateral myocardial infarction occurring in a patient receiving 5-FU chemotherapy for adenocarcinoma of the colon. The cessation of 5-FU administration and the subsequent initiation of treatment with a sublingual calcium channel blocker and nitrate resulted in a successful outcome. Although the mechanism by which 5-FU exerts its cardiotoxic effects is unknown, the resolution of the patient's chest pain and the normalization of his ECG changes with a vasodilator strongly support the vasospastic hypothesis of 5-FU cardiotoxicity.
Many hypotheses regarding 5-FU-induced cardiotoxicity have been formulated. One study postulated that 5-FUassociated cardiotoxicity is due to the uncoupling of the electromechanical mechanisms that underlie normal myocardial function, which might be mediated at the level of the cell membrane [3] . Recently, Kuzel et al. [4] suggested that 5-FU promotes a hypercoagulable state (e.g., coronary artery thrombosis) and observed a significant increase in fibrinopeptide A and a decrease in protein C activity during 5-FU administration.
The incidence of clinically apparent 5-FU cardiotoxicity is less than 10% in patients receiving the drug [5] . Patients with a history of coronary artery disease (CAD) have a significantly increased risk of 5-FU-induced cardiotoxicity [6] . Although our patient did not have a history of CAD, a large atheromatous plaque was found on coronary angiography and IVUS. Therefore, during 5-FU infusion, close, careful monitoring of patients, especially those with pre-existing CAD or CAD risk factors, is mandatory. Prophylactic cal- cium channel blockers or nitrates should be administered to patients with CAD during 5-FU administration, to prevent vasospasm [7] . One study proposed that impaired renal function is also a risk factor for 5-FU cardiotoxicity.
Although it is not clear whether the cardiotoxic metabolites undergo renal excretion, the pathophysiological effect of 5-FU on the myocardium is likely to increase with decreased renal function. Thus it is necessary to clarify which patients may benefit from optimum anti-angina prophylaxis and careful, close monitoring [1] .
The incidence of 5-FU-related cardiotoxicity appears to be dependent on the dosage and delivery system. Infusion of 5-FU, which is now being used more frequently and at higher doses instead of bolus therapy, may be a significant factor in the development of 5-FU cardiotoxicity [5] . In one study, nine patients treated with a higher-dose (> 800 mg/ 
